Iovance Q2 revenue of ~$99M beats guidance by >10%, cash runway extends into 2H 2028

Filed August 6, 2026 · Period ending August 6, 2026 · ~2 min read

Key Changes

• high

  Q2 2026 revenue of ~$99M exceeded guidance by >10%, representing ~66% year-over-year quarterly growth, signaling stronger-than-expected Amtagvi uptake in advanced melanoma.

  Exhibit 99.1 view on EDGAR →
• high

  Gross margin from cost of sales expected to reach ~56% in Q2 2026 (excluding D&A), with ~$304M cash runway into 2H 2028, reflecting manufacturing scale and efficiency gains.

  Exhibit 99.1 view on EDGAR →
• high

  Lifileucel in nonsquamous mNSCLC showed 25.6% ORR (n=39) with median duration of response not reached at 25.4 months follow-up; FDA granted Fast Track Designation, targeting 2H 2027 launch in a market ~7x U.S. melanoma.

  Exhibit 99.1 view on EDGAR →